Show simple item record

dc.contributor.authorBayarri-Lara, C.I.
dc.contributor.authorde Miguel Pérez, Diego
dc.contributor.authorOrtega, F.G.
dc.date.accessioned2019-11-26T14:12:37Z
dc.date.available2019-11-26T14:12:37Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85075014918&doi=10.3390%2fcancers11111750&partnerID=40&md5=d6ea2949dcef7d210f26d887533a82a9
dc.identifier.urihttp://hdl.handle.net/10713/11443
dc.description.abstractBackground: The prognosis of early stage non-small cell lung cancer (NSCLC) is quite disappointing and the benefits of adjuvant therapy are relatively small. Thus, there is an urgent need to identify novel prognostic and predictive biomarkers. Lung adenocarcinoma has distinct clinical-pathological characteristics and novel therapeutic strategies are under active evaluation in the adjuvant setting. Here, we investigated the prognostic impact of circulating tumor cells (CTCs) and gene and miRNA tissue expression in resectable NSCLC. Patients and methods: We assessed the association between CTC subpopulations and the outcome of resected early stage lung adenocarcinoma (ADC) patients at three different time-points (CTC1-3) (before surgery, after one month, and after six months) in comparison to squamous cell carcinoma (SCC). Furthermore, gene and miRNA tissue expression, immunoprofiling, and epithelial-to-mesenchymal transition (EMT) markers were correlated with outcome. Results: ADC (n = 47) and SCC (n = 50) revealed different tissue expression profiles, resulting in the presence of different CTC subpopulations. In ADC, miR- 155 correlated with AXL and IL6R expression, which were related to the presence of EMT CTC1 (p = 0.014 and p = 0.004). In the multivariate analysis, CTC2 was an independent prognostic factor for relapse-free survival, and CTC3 and AXL were independent prognostic for overall survival only in ADC. Neither the surgery nor the adjuvant treatment influenced the prognosis of these patients. Conclusions: Our study elucidate the prognostic impact of tissue AXL expression and the presence of CTCs after surgery in adenocarcinoma patients. Tissue AXL expression and CTC EMT activation could potentially represent biomarkers for the stratification of ADC patients that might benefit from new adjuvant therapies. Copyright 2019 by the authors.en_US
dc.description.sponsorshipThis work was supported by the Department of Health and Social Welfare of the Regional Government of Andalusia [PI-0294-2012] and Diego de Miguel Perez was supported by the PhD (2014) and the PhD International Mobility (2019) grants from the University of Granada, Spain.en_US
dc.description.urihttps://doi.org/10.3390/cancers11111750en_US
dc.language.isoen_USen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofCancers
dc.subjectAdenocarcinomaen_US
dc.subjectAXLen_US
dc.subjectBiomarkersen_US
dc.subjectCirculating tumor cellsen_US
dc.subjectEMTen_US
dc.subjectLiquid biopsyen_US
dc.subjectNSCLCen_US
dc.subjectPrognosisen_US
dc.titlePost-surgery circulating tumor cells and AXL overexpression as new poor prognostic biomarkers in resected lung adenocarcinomaen_US
dc.typeArticleen_US
dc.identifier.doi10.3390/cancers11111750


This item appears in the following Collection(s)

Show simple item record